论文部分内容阅读
目的:分析乳腺癌组织中葡萄糖转运蛋白(GLUT1、GLUT3)的表达与新辅助化疗疗效的相关性。方法:回顾性分析49例乳腺癌行新辅助化疗病人的临床病理资料和雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER-2)、核增殖抗原(Ki-67)的表达情况。同时,采用免疫组织化学方法检测乳腺癌穿刺活检组织的GLUT1和GLUT3表达水平。根据实体瘤疗效评价标准(RECIST),将新辅助化疗效果分为部分缓解(PR)、疾病稳定(SD)和疾病进展(PD)三组,分析三组病人在GLUT1和GLUT3表达水平上的差异。结果:GLUT1在化疗SD组和PD组表达显著高于PR组;GLUT3在PD组的表达显著高于PR组和SD组。结论:新辅助化疗疗效差的病人,GLUT1和GLUT3表达有升高的趋势。GLUT1和GLUT3可作为评估乳腺癌新辅助化疗疗效的预测指标。
Objective: To analyze the correlation between the expression of glucose transporter (GLUT1, GLUT3) and the efficacy of neoadjuvant chemotherapy in breast cancer. Methods: The clinical and pathological data of 49 patients with breast cancer who underwent neoadjuvant chemotherapy were retrospectively analyzed. The clinical data of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2) Antigen (Ki-67) expression. At the same time, immunohistochemistry was used to detect the expression of GLUT1 and GLUT3 in biopsies of breast cancer. The effect of neoadjuvant chemotherapy was divided into three groups: partial remission (PR), stable disease (SD) and disease progression (PD) according to RECIST standard. The differences in the expression of GLUT1 and GLUT3 between the three groups were analyzed . Results: The expression of GLUT1 in SD group and PD group was significantly higher than that in PR group. The expression of GLUT3 in PD group was significantly higher than that in PR group and SD group. Conclusions: The expression of GLUT1 and GLUT3 in patients with poor response to neoadjuvant chemotherapy has an increasing trend. GLUT1 and GLUT3 can be used as predictors of the efficacy of neoadjuvant chemotherapy in breast cancer.